When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
Joint Authors
Source
Multiple Sclerosis International
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-05-17
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment.
This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.
American Psychological Association (APA)
Alkhawajah, Mona& Oger, Joel. 2011. When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?. Multiple Sclerosis International،Vol. 2011, no. 2011, pp.1-11.
https://search.emarefa.net/detail/BIM-493580
Modern Language Association (MLA)
Alkhawajah, Mona& Oger, Joel. When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?. Multiple Sclerosis International No. 2011 (2011), pp.1-11.
https://search.emarefa.net/detail/BIM-493580
American Medical Association (AMA)
Alkhawajah, Mona& Oger, Joel. When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?. Multiple Sclerosis International. 2011. Vol. 2011, no. 2011, pp.1-11.
https://search.emarefa.net/detail/BIM-493580
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-493580
